Literature DB >> 11964901

Pros and cons of therapeutic drug monitoring of antiretroviral agents.

David M Burger1, Rob E Aarnoutse, Patricia W H Hugen.   

Abstract

Therapeutic drug monitoring has the promise to become a part of routine patient care in the treatment of HIV infection. It is known that plasma drug concentrations of protease inhibitors and non-nucleoside reverse transcriptase inhibitors are better predictors of antiviral response or toxicity than drug dose is. Furthermore, high interpatient variability is significant. In addition, therapeutic drug monitoring may be used as a direct and objective instrument to measure non-adherence. This review describes possibilities and limitations of therapeutic drug monitoring in HIV treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11964901     DOI: 10.1097/00001432-200202000-00004

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  4 in total

Review 1.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

2.  Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.

Authors:  R J Caswell; D Phillips; M Chaponda; S H Khoo; G P Taylor; M Ghanem; M Poulton; J Welch; S Gibbons; V Jackson; J S Lambert
Journal:  Int J STD AIDS       Date:  2011-01       Impact factor: 1.359

Review 3.  Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.

Authors:  Pieter L A Fraaij; Jeroen J A van Kampen; David M Burger; Ronald de Groot
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.

Authors:  J-C Wasmuth; I Lambertz; E Voigt; M Vogel; C Hoffmann; D Burger; J K Rockstroh
Journal:  Eur J Clin Pharmacol       Date:  2007-08-10       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.